Lv31
384 积分 2020-08-11 加入
One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma
26天前
已完结
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
2个月前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
6个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
6个月前
已完结
Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics
9个月前
已完结
皖公网安备34019202002308
